Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/103021
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hopkins, A. | - |
dc.contributor.author | Moghaddami, M. | - |
dc.contributor.author | Foster, D. | - |
dc.contributor.author | Proudman, S. | - |
dc.contributor.author | Upton, R. | - |
dc.contributor.author | Wiese, M. | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Drug Metabolism and Disposition, 2017; 45(1):8-16 | - |
dc.identifier.issn | 0090-9556 | - |
dc.identifier.issn | 1521-009X | - |
dc.identifier.uri | http://hdl.handle.net/2440/103021 | - |
dc.description.abstract | Leflunomide's active metabolite teriflunomide inhibits dihydro-oroate dehydrogenase (DHODH), an enzyme essential to proliferation of T-lymphocytes. As teriflunomide must reach the target site to have this effect, this study assessed the distribution of teriflunomide into T-lymphocytes, as intracellular concentrations may be a superior response biomarker to plasma concentrations. CD3 MicroBeads (MiltenyiBiotec) were used to extract CD3(+) T-cells from the peripheral blood of patients with rheumatoid arthritis whom were taking a stable dose of leflunomide. Unbound plasma and intra-CD3(+) T-cell teriflunomide concentrations were quantified using liquid chromatography-mass spectrometry (LC-MSMS). Concentration (log transformed) and partition differences were assessed through paired Student's t-tests. Sixteen patients provided plasma steady-state teriflunomide samples, and eight provided a sample 6-12 weeks later. At time-point one, the geometric mean teriflunomide concentration (range) in CD3(+) T-cells was 18.12 ug/L (6.15 - 42.26 ug/L) compared to 69.75 ug/L (32.89 - 263.1 ug/L) unbound in plasma (p<0.001). The mean partition coefficient (range) for unbound plasma teriflunomide into CD3(+) T-cells was 0.295 (0.092 - 0.632), which was significantly different from unity (p<0.001). The median (range) change in teriflunomide concentration between the two time points was 14% (-10% to 40%) in unbound plasma and -29% (-69 to 138%) for CD3(+) T-cells. Since teriflunomide concentrations in CD3(+) T-cells were lower and displayed a higher intra-individual variability than the unbound plasma concentrations, its applicability as a therapeutic drug monitoring marker may be limited. | - |
dc.description.statementofresponsibility | Ashley M Hopkins, Mahin Moghaddami, David JR Foster, Susanna M Proudman, Richard N Upton, Michael D Wiese | - |
dc.language.iso | en | - |
dc.publisher | American Society for Pharmacology and Experimental Therapeutics | - |
dc.rights | © American Society for Pharmacology and Experimental Therapeutics | - |
dc.source.uri | http://dx.doi.org/10.1124/dmd.116.071985 | - |
dc.subject | mass spectrometry/MS | - |
dc.subject | pharmacokinetics | - |
dc.title | Intracellular CD3⁺ T-lymphocyte teriflunomide concentration is poorly correlated with and has greater variability than unbound plasma teriflunomide concentration | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1124/dmd.116.071985 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Foster, D. [0000-0002-7345-4084] | - |
dc.identifier.orcid | Proudman, S. [0000-0002-3046-9884] | - |
dc.identifier.orcid | Upton, R. [0000-0001-9996-4886] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.